The stellar successes of immunotherapies that harness the power of T cells to treat solid tumors and an improved understanding of the immune systems of patients with hematologic malignancies have led to major efforts to develop immunotherapies for the treatment of patients with AML.
The authors showed that cancer stem cells upregulated the immune checkpoint molecule CD276 to evade host immune responses.
[Cell Stem Cell]
6445212 M9KYECR5 items 1 apa default asc 1
The authors discuss and summarize the important roles played by anti-programmed death ligand 1/programmed cell death ligand-1 (PD-1/PD-L1) immunotherapy and its combination with other drugs, including chemotherapy and vaccines, in the treatment of prostate cancer.
Genentech, Inc. announced the FDA Oncologic Drugs Advisory Committee voted seven to two in favor of maintaining accelerated approval of Tecentriq® in combination with chemotherapy for the treatment of adults with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1, as determined by an FDA-approved test.
6807162 nan items 1 apa default asc 1
Researchers demonstrated that programmed death cell receptor 1 (PD-1) ligation on human CD25-depleted CD4+ T cells, combined with CD3/TCR stimulation, induced their conversion into highly suppressive T cells.
6445218 EZPGG6GD items 1 apa default asc 1
Fanelli, G., Romano, M., Nova-Lamperti, E., Sunderland, M. W., Nerviani, A., Scottà, C., Bombardieri, M., Quezada, S. A., Sacks, S. H., Noelle, R. J., Pitzalis, C., Lechler, R. I., Lombardi, G., & Becker, P. D. (2021). PD-L1 signaling on human memory CD4+ T cells induces a regulatory phenotype. PLOS Biology, 19(4), e3001199. https://doi.org/10.1371/journal.pbio.3001199 Cite
Investigators demonstrated a potentially novel mechanism by which PD-L1 promoted the epithelial-mesenchymal transition (EMT) in TNBC cells by suppressing the destruction of the EMT transcription factor Snail.
Investigators used melanoma tumors arising from a genetically engineered mouse model to evaluate the efficacy of an anti-mouse PD-L1 antibody similar to the anti-human PD-L1 antibodies durvalumab and atezolizumab.
[Molecular Cancer Research]
6445218 LEDD6JZ2 items 1 apa default asc 1
Meskini, R. E., Atkinson, D., Kulaga, A., Abdelmaksoud, A., Gumprecht, M., Pate, N., Hayes, S., Oberst, M., Kaplan, I. M., Raber, P., Dyke, T. V., Sharan, S. K., Hollingsworth, R., Day, C.-P., Merlino, G., & Ohler, Z. W. (2021). Distinct biomarker profiles and TCR sequence diversity characterize the response to PD-L1 blockade in a mouse melanoma model. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.MCR-20-0881 Cite
The IOX1 and DOX combination greatly promoted T cell infiltration and activity and significantly reduced tumor immunosuppressive factors.
6445218 UPT2QLGN items 1 apa default asc 1
Bristol Myers Squibb announced that Opdivo, in combination with fluoropyrimidine- and platinum-containing chemotherapy, was approved by the FDA for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, regardless of PD-L1 expression status.
[Bristol Myers Squibb]
6445212 nan items 1 apa default asc 1
Employing qRT-PCR, Sanger sequencing, and RNA BaseScope analysis, scientists showed that human lung adenocarcinoma (LUAD) all produce a long non-coding RNA isoform of programmed death-ligand 1 (PD-L1) (PD-L1-lnc) by alternative splicing, regardless if the tumor is positive or negative for the protein PD-L1.
6445212 Q9X5DUHT items 1 apa default asc 1
The authors demonstrated that selective HDAC8 inhibition elicited effective and durable responses to immune-checkpoint blockade by co-opting adaptive immunity through enhancer reprogramming.
[Science Translational Medicine]
6445212 2I3P7IXW items 1 apa default asc 1